×
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.84 (+1.67%)
AAPL   141.38 (+1.76%)
MSFT   262.41 (+1.09%)
META   167.59 (+4.72%)
GOOGL   2,261.77 (+4.00%)
AMZN   113.73 (+3.81%)
TSLA   697.75 (+2.34%)
NVDA   149.13 (+2.69%)
NIO   22.20 (+3.93%)
BABA   119.40 (+2.93%)
AMD   74.89 (+1.66%)
MU   56.87 (+6.00%)
CGC   2.71 (-3.56%)
T   21.12 (-0.89%)
GE   61.88 (-2.61%)
F   11.15 (-1.50%)
DIS   96.96 (+0.85%)
AMC   12.68 (-6.28%)
PFE   51.52 (-1.51%)
PYPL   74.32 (+4.09%)
NFLX   185.43 (+3.05%)
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.84 (+1.67%)
AAPL   141.38 (+1.76%)
MSFT   262.41 (+1.09%)
META   167.59 (+4.72%)
GOOGL   2,261.77 (+4.00%)
AMZN   113.73 (+3.81%)
TSLA   697.75 (+2.34%)
NVDA   149.13 (+2.69%)
NIO   22.20 (+3.93%)
BABA   119.40 (+2.93%)
AMD   74.89 (+1.66%)
MU   56.87 (+6.00%)
CGC   2.71 (-3.56%)
T   21.12 (-0.89%)
GE   61.88 (-2.61%)
F   11.15 (-1.50%)
DIS   96.96 (+0.85%)
AMC   12.68 (-6.28%)
PFE   51.52 (-1.51%)
PYPL   74.32 (+4.09%)
NFLX   185.43 (+3.05%)
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.84 (+1.67%)
AAPL   141.38 (+1.76%)
MSFT   262.41 (+1.09%)
META   167.59 (+4.72%)
GOOGL   2,261.77 (+4.00%)
AMZN   113.73 (+3.81%)
TSLA   697.75 (+2.34%)
NVDA   149.13 (+2.69%)
NIO   22.20 (+3.93%)
BABA   119.40 (+2.93%)
AMD   74.89 (+1.66%)
MU   56.87 (+6.00%)
CGC   2.71 (-3.56%)
T   21.12 (-0.89%)
GE   61.88 (-2.61%)
F   11.15 (-1.50%)
DIS   96.96 (+0.85%)
AMC   12.68 (-6.28%)
PFE   51.52 (-1.51%)
PYPL   74.32 (+4.09%)
NFLX   185.43 (+3.05%)
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.84 (+1.67%)
AAPL   141.38 (+1.76%)
MSFT   262.41 (+1.09%)
META   167.59 (+4.72%)
GOOGL   2,261.77 (+4.00%)
AMZN   113.73 (+3.81%)
TSLA   697.75 (+2.34%)
NVDA   149.13 (+2.69%)
NIO   22.20 (+3.93%)
BABA   119.40 (+2.93%)
AMD   74.89 (+1.66%)
MU   56.87 (+6.00%)
CGC   2.71 (-3.56%)
T   21.12 (-0.89%)
GE   61.88 (-2.61%)
F   11.15 (-1.50%)
DIS   96.96 (+0.85%)
AMC   12.68 (-6.28%)
PFE   51.52 (-1.51%)
PYPL   74.32 (+4.09%)
NFLX   185.43 (+3.05%)

If PetMeds Is A Good Buy There Will Be A Better Signal 

Tuesday, May 10, 2022 | Thomas Hughes
If PetMeds Is A Good Buy There Will Be A Better Signal 

PetMeds Moves Up On Mixed Results 

Shares of PetMeds (NASDAQ: PETS) are rocketing higher in the wake of what we can only call a mixed report. The news wasn’t bad and it wasn’t good and it certainly isn’t enough to have shares up by 9%, not unless you factor in the short interest. The short interest was over 21% at the start of the month which is quite a weight for share prices and part of why they have been trending lower over the past several quarters. It is our guess that there is some short-covering going on right now and that this pop in prices is being used by the bears to full advantage because it is so far behind its competitors it may never catch up. 

PetMeds made its name as PetMed Express, an eCommerce delivery service specializing in pet medicine delivery. The concept was good enough to get the company in business but has come under pressure in recent years. No few competitors have emerged including Chewy.com and they are all better. Where PetMed Express operated like an online veterinary clinic its competitors did not. PetMed Express's offerings were as limited as the vet's office and when compared to online stores that combine the best of full-blown pet retail with vet and pharma it was a no-brainer for consumers. Now, PetMeds is trying to combat steadily declining revenue and earnings by making the switch to a more comprehensive pet health concept and it may not work, even with positive trends supporting the broader pet care market. 

PetMeds Has Mixed Quarter On Declining Revenue

PetMeds has seen its revenue decline for 9 of the last 13 quarters and the 4 quarters that saw growth were pandemically-boosted so they don’t count. Since the height of the pandemic, the company’s revenue has dwindled nearly 40% to a mere $66 million This is down 7.9% YOY and more in the 2-year comparison and missed the Marketbeat.com consensus by $2.13 million or about 300 basis points. Moving down to the earnings, the news is equally mixed with gross margin improving by 80 basis points but operating margin contracting by 100. This left the GAAP earnings down 11% YOY and EPS at $0.30. The good news is that margin came in a little better than expected and EPS beat by $0.02 but that’s not enough for us to get excited. What we want to see is traction and momentum in the new strategy. 


The part of this story that is the most concerning to us is the dividend. The dividend is attractive at a 5.77% yield and the company says it is committed to paying a dividend but there is risk in this picture. The payout ratio on a TTM basis is above 100% and the outlook for this year is not any better. The balance sheet is still in good shape but cash is declining and will fall further if business and/or profitability don’t pick up. What we see is happening, however, is a distribution cut and it may be a big one. 

The Technical Outlook: PetMeds Pops But We’re Not Buying It 

Price action in PetMeds popped more than 9.0% following the Q4 release but, as we said, this move is more to do with short selling and short-covering than anything else. In our view, price action is facing stiff resistance at the $24 that will be compounded by the short-term EMA. If the stock can get above those levels a reversal may be in order, until then this stock is still in a downtrend and one that we think will see a new low. 

If PetMeds Is A Good Buy There Will Be A Better Signal 

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:


Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastIs The Market Near a Bottom, Does it Matter?

Today’s interview is a little different, in that you get a LOT of market perspective from someone who’s been analyzing stocks from the ground up, for more than three decades. In this conversation, Kate chats with Nancy Zambell, the chief analyst for the Cabot Money Club Letter - and Nancy has a really deep and varied background in the financial industry - as she mentions in this interview, she’s been a banker, real estate professional, and a stock market analyst.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.